Please use this identifier to cite or link to this item:
Type: Artigo
Title: Plasma HSP90 level as a marker of early acute lymphoblastic leukemia engraftment and progression in mice
Author: Milani, Mateus
Albertoni Laranjeira, Angelo Brunelli
de Vasconcellos, Jaira Ferreira
Brandalise, Silvia Regina
Nowill, Alexandre Eduardo
Yunes, Jose Andres
Abstract: Current monitoring of acute lymphoblastic leukemia (ALL) in living mice is based on FACS analysis of blood hCD45+ cells. In this work, we evaluated the use of human IGFBP2, B2M or Hsp90 as soluble markers of leukemia. ELISA for B2M and IGFBP2 resulted in high background levels in healthy animals, precluding its use. Conversely, plasma levels of Hsp90 showed low background and linear correlation to FACS results. In another experiment, we compared Hsp90 levels with percentage of hCD45+ cells in blood, bone marrow, liver and spleen of animals weekly sacrificed. Hsp90 levels proved to be a superior method for the earlier detection of ALL engraftment and correlated linearly to ALL burden and progression in all compartments, even at minimal residual disease levels. Importantly, the Hsp90/hCD45+ ratio was not altered when animals were treated with dexamethasone or a PI3K inhibitor, indicating that chemotherapy does not directly interfere with leukemia production of Hsp90. In conclusion, plasma Hsp90 was validated as a soluble biomarker of ALL, useful for earlier detection of leukemia engraftment, monitoring leukemia kinetics at residual disease levels, and pre-clinical or mouse avatar evaluations of anti-leukemic drugs
Subject: Leucemia linfoide aguda
Country: Estados Unidos
Editor: Public Library of Science
Rights: Aberto
Identifier DOI: 10.1371/journal.pone.0129298
Date Issue: 2015
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
000356100900048.pdf1.89 MBAdobe PDFView/Open
000361043100114_errata.pdf191.61 kBAdobe PDFView/Open
000358838400164_Errata.pdf487.69 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.